DOCSLIB.ORG

SIGNIFICANT ITEMS (Sis)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
SIGNIFICANT ITEMS (Sis) SIGNIFICANT ITEMS (SIs) FY 2013 Senate Appropriations Committee Report and FY 2013 House Appropriations Committee Report Table of Contents National Cancer Institute (NCI) 1 National Heart, Lung, and Blood Institute (NHLBI) 19 National Institute of Dental and Craniofacial Research (NIDCR) 33 National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 35 National Institute of Neurological Disorders and Stroke (NINDS) 43 National Institute of Allergy and Infectious Diseases (NIAID) 51 National Institute of General Medical Sciences (NIGMS) 63 National Institute of Child Health and Human Development (NICHD) 65 National Eye Institute (NEI) 79 National Institute of Environmental Health Sciences (NIEHS) 83 National Institute of Environmental Health Sciences (NIEHS) Superfund 87 National Institute on Aging (NIA) 89 National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) 97 National Institute on Deafness and Other Communication Disorders (NIDCD) 103 National Institute of Mental Health (NIMH) 117 National Institute on Drug Abuse (NIDA) 125 National Institute on Alcohol Abuse and Alcoholism (NIAAA) 133 National Institute on Minority Health and Health Disparities (NIMHD) 135 National Center for Complementary and Alternative Medicine (NCCAM) 139 National Center for Advancing Translational Sciences (NCATS) 141 National Library of Medicine (NLM) 147 Office of the Director (OD) 149 A Access to Natural Product Collections ....................................................................................... 139 Alzheimer’s Disease ............................................................................................................. 89, 149 Amyotrophic Lateral Sclerosis [ALS] .......................................................................................... 43 Angiogenesis ................................................................................................................................... 1 Antibacterial Resistance................................................................................................................ 51 Anti-Malarial Medications ............................................................................................................ 52 Asthma .......................................................................................................................................... 19 Autism ......................................................................................................................................... 117 B Basic Behavioral Research Translation ........................................................................................ 20 Biology of Aging .......................................................................................................................... 90 Breast Cancer .................................................................................................................................. 2 Burden of Digestive Diseases ....................................................................................................... 35 C Cancer Disparities ........................................................................................................................... 3 Cardiovascular Disease ................................................................................................................. 21 Career Development Awards for Clinical Researchers .............................................................. 150 Cerebral Palsy ............................................................................................................................. 151 Children in Military Families........................................................................................................ 65 Chimpanzees ............................................................................................................................... 152 Chromosome Abnormalities ......................................................................................................... 66 Chronic Obstructive Pulmonary Disease [COPD] ........................................................................ 23 Chronic Pelvic Pain....................................................................................................................... 35 Class B Animal Dealers .............................................................................................................. 153 Clinical and Translational Science Awards [CTSAs] ................................................................. 141 Clinical Trials for Human Communication Disorders ................................................................ 103 Cognitive Interventions ................................................................................................................. 91 Collaboration With DOE ............................................................................................................ 154 Collaboration With the FDA ............................................................................................... 125, 155 Combination HIV Prevention ..................................................................................................... 118 Congenital Diaphragmatic Hernia [CDH] .................................................................................. 141 Congenital Muscular Dystrophy ................................................................................................. 156 Cystic Fibrosis [CF] .................................................................................................................... 157 D Dementia and Hearing Loss ........................................................................................................ 104 Demographic Research ........................................................................................................... 67, 92 Diabetes....................................................................................................................................... 135 Diabetes Prevention ...................................................................................................................... 36 Diabetic Eye Disease .................................................................................................................... 79 i Disaster Information Management ............................................................................................. 147 Doctors of Veterinary Medicine [DVMs] and Loan Repayment Programs ............................... 158 Down Syndrome ......................................................................................................................... 159 Drug Allergy ............................................................................................................................... 160 Duchenne Muscular Dystrophy .................................................................................................. 161 Dystonia ................................................................................................................................ 44, 142 E Early Detection, Diagnosis, and Intervention ............................................................................. 105 Eating Disorders.......................................................................................................................... 163 Education .................................................................................................................................... 126 Endocrine Disruption and Women’s Health ................................................................................. 83 Eosinophil-Associated Disorders ................................................................................................ 164 Epilepsy......................................................................................................................................... 45 F False Positives and Replications ................................................................................................. 165 Fecal Incontinence ........................................................................................................................ 37 Food Allergies ............................................................................................................................... 53 Fragile X-Associated Disorders .................................................................................................. 166 Functional Gastrointestinal Disorders [FGIDs] ............................................................................ 38 G Genetic Basis of Eye Disease ....................................................................................................... 79 Glomerular Disease ..................................................................................................................... 168 Gulf Oil Spill................................................................................................................................. 84 H Hair Cell Regeneration and Replacement ................................................................................... 106 Headache Disorders ...................................................................................................................... 46 Hearing Aids and Cochlear Implants .......................................................................................... 107 Hearing Impairment Among Children and Young Adults .......................................................... 108
Load more

Recommended publications
  • Ion Channels in Drug Discovery
    Department of Physiology and Pharmacology Karolinska Institutet, Stockholm, Sweden Thesis for doctoral degree (Ph.D.) 2008 Thesis for doctoral degree (Ph.D.) 2008 Ion Channels in Drug Discovery - focus on biological assays Ion Channels in Drug Discovery - focus on biological assays Kim Dekermendjian Ion Channels in Drug Discovery - focus on biological - focus on in Drug assays Channels Discovery Ion Kim Dekermendjian Kim Dekermendjian Stockholm 2008 Department of Physiology and Pharmacology Karolinska Institutet, Stockholm, Sweden Ion Channels in Drug Discovery - focus on biological assays Kim Dekermendjian Stockholm 2008 Main Supervisor: Bertil B Fredholm, Professor Department of Physiology and Pharmacology Karolinska Institutet. Co-Supervisor: Olof Larsson, PhD Associated Director Department of Molecular Pharmacology, Astrazeneca R&D Södertälje. Opponent: Bjarke Ebert, Adjunct Professor Faculty of Pharmaceutical Sciences, University of Copenhagen, Denmark. and Department of Electrophysiology, H. Lundbeck A/S, Copenhagen, Denmark. Examination board: Ole Kiehn, Professor Department of Neurovetenskap, Karolinska Institutet. Bryndis Birnir, PhD Docent Department of Clinical Sciences, Lund University. Bo Rydqvist, Professor Department of Physiology and Pharmacology Karolinska Institutet. All previously published papers were reproduced with permission from the publisher. Front page (a) Side view of the GABA-A model; the trans membrane domain (TMD) (bottom) spans through the lipid membrane (32 Å) and partly on the extracellular side (12 Å), while the ligand binding domain (LBD) (top) is completely extracellular (60 Å). (b) The LBD viewed from the extracellular side (diameter of 80 Å). (c) The TMD viewed from the extracellular side. Arrows and ribbons (which correspond to ȕ-strands and Į- helices, respectively) are coloured according to position in each individual subunit sequence, as well as in the TM4 of each subunit which is not bonded to the rest of the model (with permission from Campagna-Slater and Weaver, 2007 Copyright © 2006 Elsevier Inc.).
    [Show full text]
  • Exploring Non-Covalent Interactions Between Drug-Like Molecules and the Protein Acetylcholinesterase
    Exploring non-covalent interactions between drug-like molecules and the protein acetylcholinesterase Lotta Berg Doctoral Thesis, 2017 Department of Chemistry Umeå University, Sweden This work is protected by the Swedish Copyright Legislation (Act 1960:729) ISBN: 978-91-7601-644-2 Elektronisk version tillgänglig på http://umu.diva-portal.org/ Printed by: VMC-KBC Umeå Umeå, Sweden, 2017 “Life is a relationship between molecules, not a property of any one molecule” Emile Zuckerkandl and Linus Pauling 1962 i Table of contents Abstract vi Sammanfattning vii Papers covered in the thesis viii List of abbreviations x 1. Introduction 1 1.1. Drug discovery 1 1.2. The importance of non-covalent interactions 1 1.3. Fundamental forces of non-covalent interactions 2 1.4. Classes of non-covalent interactions 3 1.5. Hydrogen bonds 3 1.5.1. Definition of the hydrogen bond 3 1.5.2. Classical and non-classical hydrogen bonds 4 1.5.3. CH∙∙∙Y hydrogen bonds 5 1.6. Interactions between aromatic rings 6 1.7. Thermodynamics of binding 7 1.8. The essential enzyme acetylcholinesterase 8 1.8.1. The relevance of research focused on AChE 8 1.8.2. The structure of AChE 9 1.8.3. AChE in drug discovery 10 2. Scope of the thesis 12 3. Background to techniques and methods 13 3.1. Structure determination by X-ray crystallography 13 3.1.1. The significance of crystal structures of proteins 13 3.1.2. Data collection and structure refinement 13 3.1.3. Electron density maps 14 3.1.4.
    [Show full text]
  • What Does It Take to Be X-Class?
    Solar Flares: What Does It Take to Be X-Class? Sun Emits an X-Class Flare On August 9 3 'Uneducated Guesses' 5 Study of Abalone Yields New Insights Into Sexual Reproduction 8 Japan's Tohoku Tsunami Created Icebergs in Antarctica 11 DNA Building Blocks Can Be Made in Space, NASA Evidence Suggests 14 Genetically Modified 'Serial Killer' T-Cells Obliterate Tumors in Leukemia Patients 16 Engineers Reverse E. Coli Metabolism for Quick Production of Fuels, Chemicals 19 Diamond‘s Quantum Memory 21 New Microscope Reveals Nanoscale Details 23 Chimpanzees Are Spontaneously Generous After All, Study Shows 26 The Thrill of Boredom 28 Genetic Basis for Muscle Endurance Discovered in Animal Study 31 Scientist Develops Virus That Targets HIV: Using a Virus to Kill a Virus 34 In Auto Test in Europe, Meter Ticks Off Miles, and Fee to Driver 36 Humankind‘s Ascent Took Path of Yeast Resistance 39 With Photovoltaic Polarizers, Devices Could Be Powered by Sunlight, Own Backlight 43 Severe Low Temperatures Devastate Coral Reefs in Florida Keys 45 Billion-Year-Old Piece of North America Traced Back to Antarctica 47 When East Met West Under the Buddha‘s Gaze 50 Math Ability Is Inborn, New Research Suggests 53 Were the best world leaders mentally ill? 56 'Amino Acid Time Capsule': New Way to Date the Past 59 Reality check: Why dreams aren't what they seem 61 New Conducting Properties Discovered in Bacteria-Produced Wires 64 Genomic Biomarker Signature Can Predict Skin Sensitizers, Study Finds 66 Nanoparticle Size Is Readily Controlled to Make Stronger Aluminum
    [Show full text]
  • SKA-Athena Synergy White Paper
    SKA-Athena Synergy White Paper SKA-Athena Synergy Team July 2018. Edited by: Francisco J. Carrera and Silvia Martínez-Núñez on behalf of the Athena Community Office. Revisions provided by: Judith Croston, Andrew C. Fabian, Robert Laing, Didier Barret, Robert Braun, Kirpal Nandra Authorship Authors Rossella Cassano (INAF-Istituto di Radioastronomia, Italy). • Rob Fender (University of Oxford, United Kingdom). • Chiara Ferrari (Observatoire de la Côte d’Azur, France). • Andrea Merloni (Max-Planck Institute for Extraterrestrial Physics, Germany). • Contributors Takuya Akahori (Kagoshima University, Japan). • Hiroki Akamatsu (SRON Netherlands Institute for Space Research, The Netherlands). • Yago Ascasibar (Universidad Autónoma de Madrid, Spain). • David Ballantyne (Georgia Institute of Technology, United States). • Gianfranco Brunetti (INAF-Istituto di Radioastronomia, Italy) and Maxim Markevitch (NASA-Goddard • Space Flight Center, United States). Judith Croston (The Open University, United Kingdom). • Imma Donnarumma (Agenzia Spaziale Italiana, Italy) and E. M. Rossi (Leiden Observatory, The • Netherlands). Robert Ferdman (University of East Anglia, United Kingdom) on behalf of the SKA Pulsar Science • Working Group. Luigina Feretti (INAF-Istituto di Radioastronomia, Italy) and Federica Govoni (INAF Osservatorio • Astronomico,Italy). Jan Forbrich (University of Hertfordshire, United Kingdom). • Giancarlo Ghirlanda (INAF-Osservatorio Astronomico di Brera and University Milano Bicocca, Italy). • Adriano Ingallinera (INAF-Osservatorio Astrofisico di Catania, Italy). • Andrei Mesinger (Scuola Normale Superiore, Italy). • Vanessa Moss and Elaine Sadler (Sydney Institute for Astronomy/CAASTRO and University of Sydney, • Australia). Fabrizio Nicastro (Osservatorio Astronomico di Roma,Italy), Edvige Corbelli (INAF-Osservatorio As- • trofisico di Arcetri, Italy) and Luigi Piro (INAF, Istituto di Astrofisica e Planetologia Spaziali, Italy). Paolo Padovani (European Southern Observatory, Germany). • Francesca Panessa (INAF/Istituto di Astrofisica e Planetologia Spaziali, Italy).
    [Show full text]
  • Clinical Pharmacology of Antiмcancer Agents
    A CLINI CLINICAL PHARMACOLOGY OF NTI- C ANTI-CANCER AGENTS C AL PHARMA AN Cristiana Sessa, Luca Gianni, Marina Garassino, Henk van Halteren www.esmo.org C ER A This is a user-friendly handbook, designed for young GENTS medical oncologists, where they can access the essential C information they need for providing the treatment which could OLOGY OF have the highest chance of being effective and tolerable. By finding out more about pharmacology from this handbook, young medical oncologists will be better able to assess the different options available and become more knowledgeable in the evaluation of new treatments. ESMO ESMO Handbook Series European Society for Medical Oncology CLINICAL PHARMACOLOGY OF Via Luigi Taddei 4, 6962 Viganello-Lugano, Switzerland Handbook Series ANTI-CANCER AGENTS Cristiana Sessa, Luca Gianni, Marina Garassino, Henk van Halteren ESMO Press · ISBN 978-88-906359-1-5 ISBN 978-88-906359-1-5 www.esmo.org 9 788890 635915 ESMO Handbook Series handbook_print_NEW.indd 1 30/08/12 16:32 ESMO HANDBOOK OF CLINICAL PHARMACOLOGY OF ANTI-CANCER AGENTS CM15 ESMO Handbook 2012 V14.indd1 1 2/9/12 17:17:35 ESMO HANDBOOK OF CLINICAL PHARMACOLOGY OF ANTI-CANCER AGENTS Edited by Cristiana Sessa Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Ospedale San Raffaele, IRCCS, Unit of New Drugs and Innovative Therapies, Department of Medical Oncology, Milan, Italy Luca Gianni Ospedale San Raffaele, IRCCS, Unit of New Drugs and Innovative Therapies, Department of Medical Oncology, Milan, Italy Marina Garassino Oncology Department, Istituto Nazionale dei Tumori, Milan, Italy Henk van Halteren Department of Internal Medicine, Gelderse Vallei Hospital, Ede, The Netherlands ESMO Press CM15 ESMO Handbook 2012 V14.indd3 3 2/9/12 17:17:35 First published in 2012 by ESMO Press © 2012 European Society for Medical Oncology All rights reserved.
    [Show full text]
  • Biological Target and Its Mechanism He Zuan* Department of Pharmacology, School of Medicine,Shenzhen University, Shenzhen 518000, China
    OPEN ACCESS Freely available online Journal of Cell Signaling Editorial Biological Target and Its Mechanism He Zuan* Department of Pharmacology, School of Medicine,Shenzhen University, Shenzhen 518000, China EDITORIAL NOTE 1. There is no direct change in the biological target, but the binding of the substance stops other endogenous substances (such Biological target is whatsoever within an alive organism to which as triggering hormones) from binding to the target. Contingent some other entity (like an endogenous drug or ligand) is absorbed on the nature of the target, this effect is mentioned as receptor and binds, subsequent in a modification in its function or antagonism, ion channel blockade or enzyme inhibition. behaviour. For examples of mutual biological targets are nucleic acids and proteins. Definition is context dependent, and can refer 2. A conformational change in the target is induced by the stimulus to the biological target of a pharmacologically active drug multiple, which results in a change in target function. This change in function the receptor target of a hormone like insulin, or some other target can mimic the effect of the endogenous substance in which case of an external stimulus. Biological targets are most commonly the effect is referred to as receptor agonism or be the opposite of proteins such as ion channels, enzymes, and receptors. The term the endogenous substance which in the case of receptors is referred "biological target" is regularly used in research of pharmaceutical to as inverse agonism. to describe the nastive protein in body whose activity is altered Conservation Ecology: These biological targets are conserved by a drug subsequent in a specific effect, which may a desirable across species, making pharmaceutical pollution of the therapeutic effect or an unwanted adverse effect.
    [Show full text]
  • Uncovering New Drug Properties in Target-Based Drug-Drug Similarity Networks
    bioRxiv preprint doi: https://doi.org/10.1101/2020.03.12.988600; this version posted March 12, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. Uncovering new drug properties in target-based drug-drug similarity networks Lucret¸ia Udrescu1, Paul Bogdan2, Aim´eeChi¸s3, Ioan Ovidiu S^ırbu3,6, Alexandru Top^ırceanu4, Renata-Maria V˘arut¸5, Mihai Udrescu4,6* 1 Department of Drug Analysis, "Victor Babe¸s",University of Medicine and Pharmacy Timi¸soara,Timi¸soara,Romania 2 Ming Hsieh Department of Electrical Engineering, University of Southern California, Los Angeles, CA, USA 3 Department of Biochemistry, "Victor Babe¸s"University of Medicine and Pharmacy Timi¸soara,Timi¸soara,Romania 4 Department of Computer and Information Technology, Politehnica University of Timi¸soara,Timi¸soara,Romania 5 Faculty of Pharmacy, University of Medicine and Pharmacy of Craiova, Craiova, Romania 6 Timi¸soaraInstitute of Complex Systems, Timi¸soara,Romania * [email protected] Abstract Despite recent advances in bioinformatics, systems biology, and machine learning, the accurate prediction of drug properties remains an open problem. Indeed, because the biological environment is a complex system, the traditional approach { based on knowledge about the chemical structures { cannot fully explain the nature of interactions between drugs and biological targets. Consequently, in this paper, we propose an unsupervised machine learning approach that uses the information we know about drug-target interactions to infer drug properties.
    [Show full text]
  • MDMA, MBDB' and I! I the Classichallucinogens
    Differences Between the Mechanism I t of Action of MDMA, MBDB' and i! I the ClassicHallucinogens. i Identification of a New Therapeutic Class: Entactogens Jawi'ri", ! 7 U$ DAVID E. NICHOLS, PH.D.* The widespread use of psychedelic drugs, such as quantitative structure-activity relationships (QSARs). lysergic ac;.d diethylamide (LSD), during the 1960's and Simply stated, attempts are made to find quantitative 1970's IcC to severe reactions by governmental agencies correlations (or equations) that relate biological activity to and proscriptions against their use. However, with the fundamental properties of the molecule. This approach is high deg _e of interest in mind-altering drugs in the being widely developed in the pharmaceutical industry in United States, as evidenced by their widespread popular- order to understand more fully how particular types of ity, it wasonlyamatteroftimebeforenewdrugsappeared drugs work, and to be able to predict which additional that were developed outside of the pharmaceutical corn- molecules should be synthesized. It should also be added panics, that no equations have been developed that adequately j Nearly 70 years after its first synthesis, 3,4- correlate hallucinogenic or psychedelic activity with any methy'enedioxymethamphetamine (MDMA) was redis- particular molecular property. covered. Although it had its' more recent origin in the class In this context, it is important to define clearly the of dr. gs that is generally defined as psychedelic or hallu- type of biological activity that is being measured. It is cino enic, it clearly appears different from LSD. In hu- typical that if a molecule has several different sites of mar , MDMA induces a state of reduced anxiety and action in the brain, that each oneof these actions may be lc .red defensiveness that makes it attractive to thera- related to entirely different structural features or proper- pi .
    [Show full text]
  • Full Text (PDF)
    Review TheProgressandPromiseofMolecularImagingProbesin Oncologic Drug Development Gary J. Kelloff,1Kenneth A. Krohn,3 Steven M. Larson,4 Ralph Weissleder,5 David A. Mankoff,3 John M. Hoffman,1Jeanne M. Link, 3 Kathryn Z. Guyton,6 William C. Eckelman,2 Howard I. Scher,4 Joyce O’Shaughnessy,7 Bruce D. Cheson,8 Caroline C. Sigman,6 James L. Tatum,1 George Q. Mills,9 Daniel C. Sullivan,1and Janet Woodcock10 Abstract As addressed by the recent Food and Drug Administration Critical Path Initiative, tools are urgently needed to increase the speed, efficiency, and cost-effectiveness of drug development for cancer and other diseases. Molecular imaging probes developed based on recent scientific advances have great potential as oncologic drug development tools. Basic science studies using molecular imaging probes can help to identify and characterize disease-specific targets for oncologic drug therapy. Imaging end points, based on these disease-specific biomarkers, hold great promise to better define, stratify, and enrich study groups and to provide direct biological measures of response. Imaging-based biomarkers also have promise for speeding drug evaluation by supplementing or replacing preclinical and clinical pharmacokinetic and pharmacodynamic evaluations, including target interaction and modulation. Such analyses may be particularly valuable in early comparative studies among candidates designed to interact with the same molecular target. Finally, as response biomarkers, imaging end points that characterize tumor vitality, growth, or apoptosis can also serve as early surrogates of therapy success. This article outlines the scientific basis of oncology imaging probes and presents examples of probes that could facilitate progress. The current regulatory opportunities for new and existing probe development and testing are also reviewed, with a focus on recent Food and Drug Administra- tion guidance to facilitate early clinical development of promising probes.
    [Show full text]
  • Math and Science
    Stamford Public Schools 2010-2011 School Year Report to the Community Interim Superintendent Winifred Hamilton, Ph.D. Board of Education, 2010-2011 Polly Rauh, Ed.D., President Jackie Heftman Jerry Pia, Vice President John Leydon, Jr. Lorraine Olson, Secretary Richard Lyons, II Geoff Alswanger, Assistant Secretary Steven Polo Mayor Michael Pavia Julia Wade INTERIM SUPERINTENDENT’S HIGHLIGHTS OF THE 2010-2011 SCHOOL YEAR I am pleased to share with you the third annual Stamford Public Schools Report to the Community. In it, you will find many indicators of our system’s successes during the 2010- 2011 school year in the areas of student achievement, operational and fiscal improvements, and grant acquisitions. I am particularly proud of our students’ “You will see strong evidence that achievements in the area of college readiness. our students are motivated, engaged, More students than ever are taking four years of and ready to accept the challenges math and science. They are also taking and passing Advanced Placement of a rigorous course load.” courses in record numbers. At the middle school level, our efforts to add instructional time and standards-based curricula have led to substantial gains among multiple student groups in grade 7 reading, math, and writing. At the elementary level, the new standards-based math curriculum has been fully implemented in grades K-5, with a great deal of embedded professional development provided to staff. We are seeing steady improvement in math in the elementary grades with Stamford’s gains in math outpacing the state on the Connecticut Mastery Tests (CMTs). These data points emerge from the extremely hard work of our teachers, paraprofessionals, and administrators.
    [Show full text]
  • Sugar Coated Sugar Has Become Notorious, with Countless Claims of Its Ill Effects on Health
    HHMI BULLETIN N OV . ’11 VOL.24 • NO.04 • 4000 Jones Bridge Road Chevy Chase, Maryland 20815-6789 Hughes Medical Institute Howard www.hhmi.org Address Service Requested Sugar Coated Sugar has become notorious, with countless claims of its ill effects on health. But not all sugars are bad for you. Consider fucose, an essential sugar the body needs. Without it, neurons can’t communicate, kidneys can’t filter blood, and skin can’t stay hydrated. Chemical biologist Carolyn • Bertozzi and her group are trying to learn more about the role of fucose in www.hhmi.org development. To do this, they injected modified versions of fucose into live, single-celled zebrafish embryos. As the embryos developed, the altered fucose molecules were incorporated into the sugars that coat cell surfaces. Using a simple chemical reaction, the team attached a labeled probe molecule to the altered fucose so they could visualize its location in the developing embryo. In this image of a 19-hour-old zebrafish embryo, labeled fucose (red) glows in the peripheral cells. Just one of many ways chemistry is helping answer biological questions (see “Living Chemistry,” page 12). YEAR OF CHEMISTRY Chemists fascinated by the complexity of biology are solving problems in neuroscience, immunology, and cell signaling. v ol. 24 / no. no. / Karen Dehnert and Scott Laughlin / Bertozzi lab In This Issue: Traveling Microscope / Lemur vs Mouse / Spotlight on Science Teacher Training 04 ObservatiOns ThE GIvInG TREE The history of science overflows with captivating stories of break- Johann Kraut in 1869 and Hermann Kolbe in 1874, but then, unfortunately, throughs that led to innovative disease treatments.
    [Show full text]
  • Fifth-Year Assessment of Baylor University Major Strategic Proposal
    Fifth-Year Assessment of Baylor University Major Strategic Proposal (MSP) “Research Initiative in Terrestrial Paleoclimatology”: Faculty and Student Research Accomplishments, 2007, 2008, 2009, 2010, 2011, 2012 (partial) Executive Summary: The Terrestrial Paleoclimatology Research Initiative, an MSP initially funded by Baylor University beginning in 2007, that currently (October 29, 2012) consists of 6 Geology Faculty and one post-doc, has seen important growth and advancements of the initiative over the past 5 years, which are reported in detail in what follows. Especially noteworthy for this summary are the following: 1) Seven Ph.D. students (Drs. Ahr, Cleveland, Kahmann-Robinson, Mintz, Shunk, Stinchcomb, and Trendell) and two M.S. students (Bongino, Dhillon) have graduated, along with 12 B.S. Senior Thesis students. Three Ph.D. students (Jennings, Meier, and Michel) and two M.S. students (Culbertson and Felda) are anticipated to graduate in 2012-2013. There are currently 11 graduate students (3 M.S., 8 Ph.D.) and 4 B.S. students engaged in thesis research in the program. Three new graduate students (all Ph.D.) were recruited starting fall semester, 2012. 2) Faculty have published 97 total peer-reviewed journal articles (27 so far in 2012, 19 in 2011, 20 in 2010, 11 in 2009, 10 in 2008, and 10 in 2007), indicating a strong positive increase in research output. Of the peer-reviewed journal articles, 18 were first-authored by 7 Ph.D. students. Faculty and students gave 168 total presentations at professional meetings (24 in 2012 so far, 44 in 2011, 39 in 2010, 27 in 2009, 17 in 2008, and 17 in 2007), indicating a strong presence at professional presentations.
    [Show full text]